Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 14/20 | 0.66 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atigliflozin SCHEMBL14981898 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL15628877 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL873867 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13641405 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL19276485 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL14985137 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13644156 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL14648453 | 0.91 | SLC5A2 (0.55) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13255024 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13088388 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| EP-4676494-A1 | SYSTEMS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-01-14 | — | — | EP | claimed |
| US-12491231-B2 | Methods of treating metabolic disorders with FGF21 variants | NOVARTIS AG (CH) | 2025-12-09 | — | — | US | claimed |
| US-20250268929-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-08-28 | — | — | US | claimed |
| US-12397009-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-08-26 | — | — | US | claimed |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-17 | — | — | US | claimed |
| EP-4531810-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2025-04-09 | — | — | EP | claimed |
| WO-2024226537-A9 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NEWAMSTERDAM PHARMA B.V. (NL) | 2025-03-27 | — | — | WO | claimed |
| EP-4188353-A1 | NOVEL USES | Intra-Cellular Therapies, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-04 | — | — | US | claimed |
| WO-2023006718-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| WO-2023006747-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| WO-2023006745-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | claimed |
| US-20220378737-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-12-01 | — | — | US | claimed |
| EP-4064854-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2022-10-05 | — | — | EP | claimed |
| CN-114716425-A | Synthetic method of aromatic heterocyclic substituted methylene compound | 沧州那瑞化学科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022067724-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2022-04-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12397009-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4199/4885 |
| US-20250268929-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4132/4885 |
| US-20220378737-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ACHE 988/4885 |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885ACHE 1381/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ACHE 4329/4885 |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885ACHE 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.